Peptide data sheet
VK2735
GLP-1 · Viking VK2735
Verdict
promisingThe promising label reflects the encouraging early-phase human data reported for VK2735 in both its injectable and oral forms; it is tempered by the fact that the compound is still investigational, not FDA-approved, has no phase-3 outcome data yet, and the research-grade material sold for lab use is not the trial drug.
Quick answer
VK2735 is an investigational peptide from Viking Therapeutics that acts on two metabolic receptors, GLP-1 and GIP. It is most commonly researched for weight management, and it is notable for being developed in both an injectable and an oral tablet form. It is still investigational and not FDA-approved; research-grade VK2735 sold for laboratory use is not the trial drug.
- Class
- Dual agonist (GLP-1 / GIP receptor)
- Half-life
- reported as long enough to support once-weekly injectable research dosing; the oral form is dosed on a separate schedule
- FDA status
- Not FDA-approved. VK2735 is an investigational compound still in clinical trials; research-grade material sold for lab use is intended for laboratory research only.
- WADA banned?
- No
Which form actually works?
Injectable (subcutaneous)
Promising
The injectable form is where VK2735's most-discussed human data sits — the phase-2 VENTURE obesity study reported its weight results here. People report interest in this form because it matches how the compound was actually studied.
Oral (tablet)
Unproven
An oral tablet form is a genuine part of Viking's program and a big reason for the attention, since most metabolic peptides are injection-only. But the oral data is earlier-stage than the injectable data, so the evidence sits lower here.